Publisher details
National Academy Press
located at :
Washington, D.C.
|
Available items(s) from this publisher (4)
Add the result to your basket Make a suggestion Refine your search Apply to external sources
ISBN : 978-0-309-21435-3 : $ 72,86
Languages : English (eng)
Descriptors: Indexation
Electronic books ; Encephalitis, Varicella Zoster ; Epidemiology ; Evidence-Based Practice ; Influenza Vaccines ; Papillomavirus Vaccines ; United States ; Vaccines
Classification
QW 805 Vaccines. Antitoxins. ToxoidsAbstract:
In 1900, for every 1000 babies born in the United States, 100 would die before their first birthday, often due to infectious diseases. Today, vaccines exist for many viral and bacterial diseases. The cornerstone of the vaccine safety system in the United States is the National Childhood Vaccine Injury Act. This legislation was intended to bolster vaccine research and development through federal coordination of vaccine initiatives, and by providing relief to vaccine manufacturers facing financial burdens. A key component of the legislation required the Department of Health and Human Services to collaborate with the Institute of Medicine to assess concerns about the safety of vaccines and potential adverse effects, especially in children.
The Adverse Effects of Vaccines reviews the epidemiological, clinical, and biological evidence regarding adverse health effects associated with specific vaccines covered by the Vaccine Injury Compensation Program including varicella zoster vaccine, influenza vaccines, hepatitis B vaccine, and the human papillomavirus vaccine, among others. For each possible adverse event, the report reviews prior studies, summarizes their findings, and evaluates the epidemiological evidence. It finds that while no vaccine is 100% safe, very few adverse events are shown to be caused by vaccines.
In addition, the evidence shows that vaccines do not cause several conditions of recent concern. For example, the MMR vaccine is not associated with autism or childhood diabetes. The DTaP vaccine is also not associated with diabetes and the influenza vaccine given as a shot does not exacerbate asthma. The Adverse Effects of Vaccines will be of special interest to the National Vaccine Program Office, the Centers for Disease Control and Prevention, vaccine safety researchers and manufacturers, parents, caregivers, and health professionals in the private and public sectors.Contents note:
SUMMARY 1 -- Charge to the Committee 2 -- Assessing the Weight of Evidence 2 -- Causality Assessment 5 -- Causality Conclusions 7 -- Susceptibility 9 -- Concluding Comment 9 -- References 24 -- 1 INTRODUCTION 25 -- Charge to the Committee 27 -- Committee Process 28 -- Outline of the Report 28 -- References 33 -- 2 APPROACH 35 -- Literature Searching 35 -- Weight of Evidence 36 -- Causality Assessment 41 -- Special Considerations 45 -- References 48 -- 3 EVALUATING BIOLOGICAL MECHANISMS OF ADVERSE EVENTS 51 -- Latency Between Antigen Exposure and Peak Adaptive Immune Response 51 -- Immune-Mediated Mechanisms 52 -- Viral Activity 66 -- Injection-Related Adverse Events 67 -- Coagulation and Hypercoagulable States 69 -- Increased Susceptibility 70 -- Alterations in Brain Development 73 -- Contribution of Animal Models 76 -- References 79 -- 4 MEASLES, MUMPS, AND RUBELLA VACCINE 89 -- Introduction 89 -- Measles Inclusion Body Encephalitis 93 -- Encephalitis and Encephalopathy 95 -- Febrile Seizures 100 -- Afebrile Seizures 105 -- Meningitis 107 -- Ataxia 110 -- Autism 112 -- Acute Disseminated Encephalomyelitis 115 -- Transverse Myelitis 116 -- Optic Neuritis 117 -- Neuromyelitis Optica 119 -- Multiple Sclerosis Onset in Adults 120 -- Multiple Sclerosis Onset in Children 122 -- Guillain-Barré Syndrome 123 -- Chronic Inflammatory Disseminated Polyneuropathy 124 -- Opsoclonus Myoclonus Syndrome 125 -- Brachial Neuritis 125 -- Anaphylaxis 126 -- Transient Arthralgia in Women 130 -- Transient Arthralgia in Children 134 -- Chronic Arthralgia in Women 137 -- Chronic Arthritis in Women 140 -- Chronic Arthropathy in Children 143 -- Arthropathy in Men 144 -- Type 1 Diabetes 146 -- Hepatitis 149 -- Chronic Fatigue Syndrome 150 -- Fibromyalgia 151 -- Hearing Loss 151 -- References 196 -- 5 VARICELLA VIRUS VACCINE 211 -- Introduction 211 -- Disseminated Oka VZV Without Other Organ Involvement 213 -- Disseminated Oka VZV with Other Organ Involvement 219 -- Vaccine Strain Viral Reactivation Without Other Organ Involvement 224 -- Vaccine Strain Viral Reactivation with Other Organ Involvement 228 -- Encephalopathy 233 -- Seizures 233 -- Cerebellar Ataxia 235 -- Acute Disseminated Encephalomyelitis 236 -- Transverse Myelitis 237 -- Guillain-Barré Syndrome 238 -- Small Fiber Neuropathy 239 -- Anaphylaxis 239 -- Onset or Exacerbation of Arthropathy 242 -- Stroke 243 -- Thrombocytopenia 244 -- References 248 -- 6 INFLUENZA VACCINE 257 -- Introduction 257 -- Encephalitis and Encephalopathy 262 -- Seizures 264 -- Acute Disseminated Encephalomyelitis 267 -- Optic Neuritis 269 -- Neuromyelitis Optica 271 -- Multiple Sclerosis Onset in Adults 271 -- Multiple Sclerosis Relapse in Adults 273 -- Guillain-Barré Syndrome 275 -- Chronic Inflammatory Disseminated Polyneuropathy 281 -- Bell’s Palsy 282 -- Brachial Neuritis 284 -- Small Fiber Neuropathy 285 -- Anaphylaxis 285 -- Inactivated Influenza Vaccine and Asthma Exacerbation or Reactive Airway Disease -- Episodes in Children and Adults 288 -- Live Attenuated Influenza Vaccine and Asthma Exacerbation or Reactive Airway Disease -- Episodes in Children Younger Than 5 Years of Age 293 -- Live Attenuated Influenza Vaccine and Asthma Exacerbation or Reactive Airway Disease -- Episodes in Persons 5 Years of Age or Older 298 -- Onset or Exacerbation of Systemic Lupus Erythematosus 301 -- Onset or Exacerbation of Vasculitis 304 -- Polyarteritis Nodosa 306 -- Onset or Exacerbation of Arthropathy 307 -- Stroke 308 -- Myocardial Infarction 309 -- Fibromyalgia 311 -- All-Cause Mortality 311 -- Oculorespiratory Syndrome 313 -- References 354 -- 7 HEPATITIS A VACCINE 369 -- Introduction 369 -- Acute Disseminated Encephalomyelitis 370 -- Transverse Myelitis 371 -- Multiple Sclerosis 372 -- Guillain-Barré Syndrome 373 -- Chronic Inflammatory Disseminated Polyneuropathy 374 -- Bell’s Palsy 374 -- Anaphylaxis 375 -- Autoimmune Hepatitis 376 -- References 378 -- 8 HEPATITIS B VACCINE 381 -- Introduction 381 -- Encephalitis and Encephalopathy 383 -- Seizures 383 -- Acute Disseminated Encephalomyelitis 385 -- Transverse Myelitis 386 -- Optic Neuritis 387 -- Neuromyelitis Optica 389 -- Multiple Sclerosis Onset in Adults 390 -- Multiple Sclerosis Onset in Children 392 -- Multiple Sclerosis Relapse in Adults 394 -- Multiple Sclerosis Relapse in Children 395 -- First Demyelinating Event in Adults 396 -- First Demyelinating Event in Children 399 -- Guillain-Barré Syndrome 400 -- Chronic Inflammatory Disseminated Polyneuropathy 401 -- Brachial Neuritis 402 -- Anaphylaxis 402 -- Erythema Nodosum 403 -- Onset or Exacerbation of Systemic Lupus Erythematosus 404 -- Onset or Exacerbation of Vasculitis 406 -- Onset or Exacerbation of Polyarteritis Nodosa 409 -- Onset or Exacerbation of Psoriatic Arthritis 411 -- Onset or Exacerbation of Reactive Arthritis 412 -- Onset or Exacerbation of Rheumatoid Arthritis 414 -- Onset or Exacerbation of Juvenile Idiopathic Arthritis 416 -- Type 1 Diabetes 418 -- Fibromyalgia 420 -- References 431 -- 9 HUMAN PAPILLOMAVIRUS VACCINE 441 -- Introduction 441 -- Acute Disseminated Encephalomyelitis 442 -- Transverse Myelitis 443 -- Neuromyelitis Optica 444 -- Multiple Sclerosis 444 -- Guillain-Barré Syndrome 445 -- Chronic Inflammatory Disseminated Polyneuropathy 446 -- Brachial Neuritis 447 -- Amyotrophic Lateral Sclerosis 447 -- Anaphylaxis 449 -- Transient Arthralgia 450 -- Pancreatitis 451 -- Thromboembolic Events 452 -- Hypercoagulable States 453 -- References 455 -- 10 DIPHTHERIA TOXOID-, TETANUS TOXOID-, AND ACELLULAR PERTUSSISCONTAINING -- VACCINES 457 -- Introduction 457 -- Encephalitis and Encephalopathy 461 -- Infantile Spasms 464 -- Seizures 465 -- Ataxia 468 -- Autism 468 -- Acute Disseminated Encephalomyelitis 469 -- Transverse Myelitis 470 -- Optic Neuritis 471 -- Multiple Sclerosis Onset in Adults 472 -- Multiple Sclerosis Relapse in Adults 474 -- Multiple Sclerosis Relapse in Children 476 -- Guillain-Barré Syndrome 477 -- Chronic Inflammatory Disseminated Polyneuropathy 478 -- Opsoclonus Myoclonus Syndrome 480 -- Bell’s Palsy 480 -- Anaphylaxis 482 -- Chronic Urticaria 483 -- Serum Sickness 484 -- Arthropathy 485 -- Type 1 Diabetes 487 -- Myocarditis 490 -- Fibromyalgia 491 -- Sudden Infant Death Syndrome 491 -- Immune Thrombocytopenic Purpura 492 -- References 506 -- 11 MENINGOCOCCAL VACCINE 515 -- Introduction 515 -- Encephalitis and Encephalopathy 517 -- Acute Disseminated Encephalomyelitis 518 -- Transverse Myelitis 519 -- Multiple Sclerosis 519 -- Guillain-Barré Syndrome 520 -- Chronic Inflammatory Disseminated Polyneuropathy 521 -- Anaphylaxis 522 -- Chronic Headache 523 -- References 526 -- 12 INJECTION-RELATED ADVERSE EVENTS 529 -- Complex Regional Pain Syndrome 529 -- Deltoid Bursitis 531 -- Syncope 533 -- References 538 -- 13 CONCLUDING COMMENTS 541 -- References 545Link for e-copy: http://www.nap.edu/catalog.php?record_id=13164 Format of e-copy: PDF [Open Access] Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=2712 At what price? / Charles L. Schultze ; Christopher D. Mackie ; National Research Council (USA) / Washington, D.C. : National Academy Press (2002)
ISBN : 978-0-309-07442-1 : 26,67 €
Languages : English (eng)
Descriptors: Classification
HB 235 Government price policy
Indexation
Consumer price indexes ; Cost and standard of living ; Economic indicators ; Index numbers (Economics) ; Prices ; Statistical methods ; United StatesLink for e-copy: https://ecommunities.belgium.be/ecomfr/start/Schultze_CL_At_What_Prize_2002.pdf? [...] Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=141 Hold
Place a hold on this item
Copies (1)
Barcode Call number Media type Location Section Status 10273-00396 ONLINE Book KCE Library (10.124) Available
ISBN : 978-0-309-06480-4 : € 34,16
Languages : English (eng)
Descriptors: Classification
QZ 266 Neoplasms. Cysts -- Therapy
Indexation
Electronic books ; Neoplasms ; Quality control ; Quality of Health Care ; Therapeutics ; United StatesAbstract: We all want to believe that when people get cancer, they will receive medical care of the highest quality. Even as new scientific breakthroughs are announced, though, many cancer patients may be getting the wrong care, too little care, or too much care, in the form of unnecessary procedures.
How close is American medicine to the ideal of quality cancer care for every person with cancer? Ensuring Quality Cancer Care provides a comprehensive picture of how cancer care is delivered in our nation, from early detection to end-of-life issues. The National Cancer Policy Board defines quality care and recommends how to monitor, measure, and extend quality care to all people with cancer. Approaches to accountability in health care are reviewed.
What keeps people from getting care? The book explains how lack of medical coverage, social and economic status, patient beliefs, physician decision-making, and other factors can stand between the patient and the best possible care. The board explores how cancer care is shaped by the current focus on evidence-based medicine, the widespread adoption of managed care, where services are provided, and who provides care. Specific shortfalls in the care of breast and prostate cancer are identified. A status report on health services research is included.
Ensuring Quality Cancer Care offers wide-ranging data and information in clear context. As the baby boomers approach the years when most cancer occurs, this timely volume will be of special interest to health policy makers, public and private healthcare purchasers, medical professionals, patient advocates, researchers, and people with cancer.
Contents note: 1 INTRODUCTION 13 -- Role of the National Cancer Policy Board, 14 -- Framework of the Report, 15 -- 2 THE CANCER CARE “SYSTEM” 18 -- Elements of the Federal Cancer Care Effort, 18 -- Elements of Cancer Care, 20 -- Individuals Receiving Cancer Care, 20 -- Trajectory of Cancer Care, 22 -- Providers of Cancer Care, 26 -- Sites of Cancer Care, 30 -- The Intersection of Cancer Care and Research, 34 -- Financial Costs of Cancer Care, 35 -- Impact of a Changing Health Care System on Cancer Care, 36 -- Managed Care, 37 -- Self-Funded Health Insurance Plans, 41 -- Key Findings, 41 -- 3 ENSURING ACCESS TO CANCER CARE 46 -- Evidence of Access Problems, 47 -- Why Do These Differences Exist? 47 -- Financial Barriers to Access to Cancer Care, 48 -- Review of the Literature, by Phase of Care, 50 -- Phase 1: Early Detection, 50 -- Phase 2: Evaluation of Abnormal Screening -- Phase 3: Cancer Treatment, 58 -- Phase 4: Posttreatment Surveillance and Recurrence Care, 63 -- Phase 5: End-of-Life Care, 63 -- Key Findings, 66 -- 4 DEFINING AND ASSESSING QUALITY CANCER CARE 79 -- Defining Quality of Care, 79 -- Why Measure Quality of Cancer Care? 80 -- How Is Quality Measured? 80 -- Structural Quality, 80 -- Process Quality, 81 -- Outcomes, 84 -- Variations in Care, 88 -- How Is Quality-of-Care Information Collected? 88 -- Evidence of Cancer Care Quality Problems, 90 -- Breast Cancer, 91 -- Prostate Cancer, 103 -- Key Findings, 108 -- 5 HEALTH CARE DELIVERY AND QUALITY OF CANCER CARE 116 -- Evaluating the Strength of Evidence from Health Services Research, 117 -- Case Volume for Hospitals or Individual Physicians, 118 -- High-Risk Cancer Surgery, 119 -- Prostate Cancer, 125 -- Breast Cancer Surgery, 126 -- Evidence on the Volume–Outcome Relationship from Other Countries, 126 -- Specialization, 128 -- Specialization of Facilities, 128 -- Specialization of Physicians, 130 -- Managed Care Versus Fee-for-Service Care, 133 -- Key Findings, 137 -- 6 CANCER CARE QUALITY ASSURANCE 144 -- Quality Assurance: An Individual Consumer Perspective, 145 -- Choosing Insurers, 145 -- Choosing Physicians and Hospitals, 146 -- Choosing Treatment Options, 148 -- Use of Quality Information by Consumers, 148 -- Quality Assurance: A Market Approach, 150 -- Quality Assurance: The Public-Sector Approach, 151 -- Health Care Financing Administration, 152 -- Public Health Monitoring, 154 -- Agency for Health Care Policy and Research, 154 -- Quality Assurance: The Health Care Professional Approach, 155 -- Joint Commission on Accreditation of Healthcare Organizations, 155 -- National Committee for Quality Assurance, 156 -- American Accreditation Health Care Commission, Inc./URAC, 158 -- Foundation for Accountability, 158 -- American College of Surgeons’ Commission on Cancer, 158 -- Association of Community Cancer Centers, 160 -- Quality Improvement Within Health Care Organizations, 163 -- Practice Guidelines, 164 -- Key Findings, 174 -- 7 HEALTH SERVICES RESEARCH IN CANCER CARE 180 -- What Is Health Services Research? 180 -- Status of Cancer-Related Health Services Research, 181 -- Research Support, 184 -- Federally Sponsored Research, 184 -- Department of Health and Human Services, 184 -- Department of Defense, 199 -- Department of Veterans Affairs, 202 -- Private Organizations Funding Research, 203 -- American Cancer Society, 203 -- The Cochrane Collaboration, 207 -- Key Findings, 207 -- 8 FINDINGS AND RECOMMENDATIONS 211 -- What Is the State of the Cancer Care “System”? 214 -- What Is Quality Cancer Care and How Is It Measured? 215 -- What Problems Are Evident in the Quality of Cancer Care and What Steps -- Can Be Taken to Improve Care? 216 -- How Can We Improve What We Know About the Quality of Cancer Care? 221 -- What Steps Can Be Taken to Overcome Barriers of Access to Quality Cancer Care? 223 -- GLOSSARY 226 -- ACRONYMS 231 -- INDEX 235 Link for e-copy: http://www.nap.edu/openbook.php?record_id=6467&page=R1 Format of e-copy: Webpage Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=2450
ISBN : 978-0-309-16425-2 : € 0,00
Languages : English (eng)
Descriptors: Classification
W 84.3 Health Services Research (General)
Indexation
Comparative Effectiveness Research ; Electronic books ; Outcome and Process Assessment (Health Care) ; Standards ; United StatesAbstract:
Healthcare decision makers in search of reliable information that compares health interventions increasingly turn to systematic reviews for the best summary of the evidence. Systematic reviews identify, select, assess, and synthesize the findings of similar but separate studies, and can help clarify what is known and not known about the potential benefits and harms of drugs, devices, and other healthcare services. Systematic reviews can be helpful for clinicians who want to integrate research findings into their daily practices, for patients to make well-informed choices about their own care, for professional medical societies and other organizations that develop clinical practice guidelines.
Too often systematic reviews are of uncertain or poor quality. There are no universally accepted standards for developing systematic reviews leading to variability in how conflicts of interest and biases are handled, how evidence is appraised, and the overall scientific rigor of the process.
In Finding What Works in Health Care the Institute of Medicine (IOM) recommends 21 standards for developing high-quality systematic reviews of comparative effectiveness research. The standards address the entire systematic review process from the initial steps of formulating the topic and building the review team to producing a detailed final report that synthesizes what the evidence shows and where knowledge gaps remain.
Finding What Works in Health Care also proposes a framework for improving the quality of the science underpinning systematic reviews. This book will serve as a vital resource for both sponsors and producers of systematic reviews of comparative effectiveness research.
Contents note: Front Matter (R1-R22) -- Summary (1-16) -- 1 Introduction (17-44) -- 2 Standards for Initiating a Systematic Review (45-80) -- 3 Standards for Finding and Assessing Individual Studies (81-154) -- 4 Standards for Synthesizing the Body of Evidence (155-194) -- 5 Standards for Reporting Systematic Reviews (195-222) -- 6 Improving the Quality of Systematic Reviews: Discussion, Conclusions, and Recommendations (223-234) -- Appendix A: Abbreviations and Acronyms (235-238) -- Appendix B: Glossary (239-242) -- Appendix C: Workshop Agenda and Questions to Panelists (243-248) -- Appendix D: Expert Guidance for Chapter 2: Standards for Initiating a Systematic Review (249-264) -- Appendix E: Expert Guidance for Chapter 3: Standards for Finding and Assessing Individual Studies (265-280) -- Appendix F: Expert Guidance for Chapter 4: Standards for Synthesizing the Body of Evidence (281-290) -- Appendix G: Expert Guidance for Chapter 5: Standards for Reporting Systemic Reviews (291-302) -- Appendix H: Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Checklist (303-306) -- Appendix I: Committee Biographies (307-318) Link for e-copy: http://www.nap.edu/catalog.php?record_id=13059 Format of e-copy: PDF [Open Access] (1,49 MB) Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=2696
